In this study, we present a case of an inoperable stage IIIA BRAF V600E mutation NSCLC patient who received perioperative targeted therapy with dabrafenib and trametinib, subsequently underwent surgery, and achieved pCR. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.